【摘要】 目的探讨重组人干扰素α-1b雾化治疗小儿疱疹性咽峡炎的临床疗效及安全性。方法将100例疱疹性咽峡炎患儿按随机数字表法分为观察组和对照组,每组50例。2组均给予一般治疗,包括营养支持、降温、补液等对症治疗;对照组在常规治疗基础上采用利巴韦林注射液治疗;观察组在常规治疗基础上给予重组人干扰素α-1b注射液治疗。比较2组临床疗效、临床症状缓解时间(包括退热时间、流涎消失时间、疱疹消退时间等)与住院时间,观察2组治疗期间不良反应发生情况。结果观察组治疗总有效率较对照组显著升高,差异有统计学意义(96%比80%,χ~2=6.061、P<0.01);观察组临床症状缓解时间与住院时间均较对照组显著缩短,差异均具有统计学意义(均P<0.05);观察组不良反应发生率较对照组显著降低,差异有统计学意义(4%比24%,χ~2=8.306、P<0.01)。结论重组人干扰素α-1b治疗小儿疱疹性咽峡炎临床疗效较好,可明显缩短症状及体征恢复时间,且安全性较高。更多还原

【Abstract】 Objective To investigate the clinical efficacy and safety of nebulized recombinant human interferon α-1 b in the treatment of herpangina in children.Methods A total of 100 children with herpangina were randomly divided into two groups,with 50 children in each group.All children were given nutritional support,hypothermia,fluid infusion and other symptomatic treatment.In addition,these children were assigned to received either ribavirin injection(control group) or nebulized recombinant human interferon α-1 b(observation group).Clinical efficacy,time to symptom remission(fever abatement,salivate disappearance,herpes regression,etc.),length of hospital stay and incidence of adverse reactions were compared between the two groups.ResultsThe total efficiency in observation group was higher than that in control group(96% vs 80%,χ~2=6.061,P<0.01).The time to symptom remission in observation group was shorter than that in control group(P<0.05).The incidence of adverse reactions in observation group was lower than that in control group(4% vs 24%,χ~2=8.306,P<0.01).Conclusion The recombinant human interferon α-1 b is an effective and safe treatment for herpangina in children,which can significantly shorten the recovery time of symptoms and signs.更多还原